DIAGENS-B (02526.HK) saw its shares surge more than 9% during Monday's trading session, climbing 9.42% to HK$569 at the time of writing, with turnover reaching HK$17.3774 million and intraday gains peaking at over 11%. The stock has now advanced an impressive 474.75% year-to-date.
The strong performance comes as the broader medical equipment and supplies sector rallied 4.51% on the day, with sector beta and stock-specific alpha working in tandem to drive DIAGENS-B higher. The catalysts trace back to August 21, when Hang Seng Indexes Company announced its quarterly index review results, with the associated changes scheduled to take effect on September 7.
DIAGENS-B has now met the eligibility criteria for inclusion in the Stock Connect southbound trading channel, and notably, it is the only company added to the Hang Seng Biotechnology Index during this review period. According to research from SPDB International, passive funds tracking the Hang Seng Index, Hang Seng Tech Index, and Hang Seng China Enterprises Index collectively manage approximately HK$796.3 billion in assets, which is expected to generate around HK$38.6 billion in two-way fund flows. With the Stock Connect inclusion approaching, sentiment around position-building has been heating up.
The company has developed its proprietary iMedImage® medical imaging foundation model, which serves as the basis for the iMedLoop™ medical imaging AI research and production acceleration platform. This three-tier architecture—foundation model, platform, and products—creates a fully integrated commercial loop for AI-driven medical applications, positioning DIAGENS-B as a global industrial platform company in medical imaging AI.
Around its foundation model, DIAGENS-B has established a three-layer capability system: at the base layer, iMedImage® delivers cross-modal, cross-organ, and cross-disease imaging understanding and reasoning; the middle layer comprises iMedStudio™, iMedMaaS®, and DoctorBench® as a standardized toolchain covering data processing, annotation quality control, model training, evaluation, and deployment; and since July, iMedLoop™ has connected data ingestion, model training, unified evaluation, release, deployment, and application feedback into a seamless loop. The company remains committed to iterating its foundation models, developing specialized clinical models, and expanding hospital deployment, driving medical imaging AI toward platform-based and large-scale application.